Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
10 avr. 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
18 janv. 2024 09h00 HE
|
Vivtex
Cambridge/Boston, MA, USA – 18th January 2024. Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins,...
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
04 janv. 2024 02h00 HE
|
Sitryx Therapeutics
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 02h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 02h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
Global Ankylosing Spondylitis Market is Projected to Reach $7.29 Billion by 2027: Leading Players Pfizer, AbbVie, and Novartis Drive Advances in Treatment Options
12 oct. 2023 07h03 HE
|
Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ankylosing spondylitis...
Immune Thrombocytopenia Market Set to Reach USD 3.39 Billion by 2031: Key Trends and Advancements
10 oct. 2023 04h28 HE
|
Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Immune Thrombocytopenia Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global immune...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
06 déc. 2022 08h10 HE
|
Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...